EAACI Congress 2025 – Breaking Boundaries in Allergy, Asthma, and Clinical Immunology: Integrating Planetary Health for a Sustainable Future
ZURICH, March 18, 2025 (GLOBE NEWSWIRE) -- The European Academy of Allergy…
Positive results from the TEZSPIRE Phase III WAYPOINT trial highlight rapid and sustained effect in chronic rhinosinusitis with nasal polyps
TEZSPIRE significantly reduced nasal congestion, polyp size and nearly eliminated the need…
Revolo to Present at the 2025 AAAAI / WAO Joint Congress
February 10, 2025 12:00 ET | Source: Revolo Biotherapeutics GAITHERSBURG, Md. and…
ALKs house dust mite tablet (ACARIZAX) now recommended by NICE for use in the UK health system
ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the…
ALK licenses rights to neffy, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis)
ALK (ALKB:DC / OMX: ALK B) today announced that it has entered…